Chloroquine

Generic Name
Chloroquine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H26ClN3
CAS Number
54-05-7
Unique Ingredient Identifier
886U3H6UFF
Background

Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other c...

Indication

Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
...

Associated Conditions
Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria
Associated Therapies
-
Clinical Trials
Related News

TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014

First Posted Date
2020-01-09
Last Posted Date
2023-07-21
Lead Sponsor
Research Institute for Tropical Medicine, Philippines
Target Recruit Count
159
Registration Number
NCT04222088

Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...

First Posted Date
2019-05-16
Last Posted Date
2022-07-12
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
252
Registration Number
NCT03952650
Locations
🇲🇱

Malaria Vaccine Center STTB/MRTC, Bamako, Mali

Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine

First Posted Date
2018-09-27
Last Posted Date
2018-09-27
Lead Sponsor
Tanta University
Target Recruit Count
60
Registration Number
NCT03687905
Locations
🇪🇬

Fatma Gheet, Tanta, Egypt

Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients

Phase 2
Active, not recruiting
Conditions
Vivax Malaria
G6PD Deficiency
Interventions
Drug: Chloroquine
Drug: Primaquine
First Posted Date
2018-05-18
Last Posted Date
2023-03-29
Lead Sponsor
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Target Recruit Count
106
Registration Number
NCT03529396
Locations
🇧🇷

Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil

🇧🇷

Centro de Pesquisa em Medicina Tropical (Cepem), Porto Velho, RO, Brazil

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

First Posted Date
2018-02-28
Last Posted Date
2022-04-28
Lead Sponsor
Sanofi
Target Recruit Count
84
Registration Number
NCT03449758
Locations
🇫🇷

Investigational Site Number 250014, Caen, France

🇫🇷

Investigational Site Number 250006, Besancon, France

🇫🇷

Investigational Site Number 250016, Bordeaux, France

and more 30 locations

Dose Escalation PfSPZ-CVac

First Posted Date
2017-03-20
Last Posted Date
2021-06-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
55
Registration Number
NCT03083847
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

CiPA Phase 1 ECG Biomarker Validation Study

First Posted Date
2017-03-03
Last Posted Date
2020-01-18
Lead Sponsor
Food and Drug Administration (FDA)
Target Recruit Count
60
Registration Number
NCT03070470
Locations
🇺🇸

Spaulding Clinical Research, West Bend, Wisconsin, United States

Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults

First Posted Date
2016-12-19
Last Posted Date
2019-12-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
62
Registration Number
NCT02996695
Locations
🇲🇱

University of Bamako - Epidemiology of Parasitic Diseases - Malaria Research and Training Center, Sikasso, Mali

Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

Phase 2
Recruiting
Conditions
Atrial Fibrillation
Interventions
Drug: Chloroquine Phosphate
First Posted Date
2016-10-13
Last Posted Date
2019-08-19
Lead Sponsor
University of South Florida
Target Recruit Count
40
Registration Number
NCT02932007
Locations
🇺🇸

University of South Florida, Tampa, Florida, United States

G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria

First Posted Date
2016-08-23
Last Posted Date
2020-10-14
Lead Sponsor
University of Oxford
Target Recruit Count
1000
Registration Number
NCT02876549
Locations
🇦🇫

Dr. Ghulam Rahim Awab MD, Jalalabad, Nangarha, Afghanistan

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy